Modernavs.Neurocrine Biosciences
MRNA vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 1.5× larger than Neurocrine Biosciences by market cap; year to date, Moderna leads (+131.5% vs +24.9%).
Side by side
| MRNA | NBIX | |
|---|---|---|
| Market cap | $27.2B | $17.7B |
| Price | $68.27 | $177.11 |
| Today | −10.8% | −1.9% |
| Return YTD | +131.5% | +24.9% |
| Return 1Y | +99.2% | +31.3% |
| P/E | — | 26.4 |
| P/S | 12.2 | 5.7 |
| P/B | 3.7 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
ModernaMRNA
American biotech company based on mRNA technology — known for the covid vaccine, with a pipeline in vaccines and oncology.
Full MRNA profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where MRNA and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →